Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classifica tra le azioni #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Prezzo delle azioni
$0.2483
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$2.30M
Variazione (1 giorno)
-3.39%
Variazione (1 anno)
-89.01%
Paese
US
Scambia Ensysce Biosciences, Inc. (ENSC)

Categoria

Healthcare
Ricavi di Ensysce Biosciences, Inc. (ENSC)
Ricavi nel Jun 2026 TTM: $1.16M
Secondo gli ultimi rapporti finanziari di Ensysce Biosciences, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $1.16M. Nel 2023, l'azienda ha registrato ricavi di $2.23M una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $2.52M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Ensysce Biosciences, Inc. da 2017 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $1.16M -77.65%
2024 $5.21M 133.53%
2023 $2.23M -11.59%
2022 $2.52M -28.54%
2021 $3.53M -10.18%
2020 $3.93M 122.86%
2019 $1.76M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,084,168.43%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 191,257.15%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 517,052.77%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 1,352,139.48%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH